Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Evolutionary Tree Capital Management LLC

Evolutionary Tree Capital Management LLC reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,115 shares of the biotechnology company's stock after selling 2,638 shares during the quarter. Ascendis Pharma A/S accounts for 4.2% of Evolutionary Tree Capital Management LLC's portfolio, making the stock its 8th largest position. Evolutionary Tree Capital Management LLC's holdings in Ascendis Pharma A/S were worth $4,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth about $886,000. Nomura Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 42.5% during the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock worth $2,688,000 after buying an additional 5,371 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth approximately $1,101,000. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Finally, Exome Asset Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 119.2% in the 3rd quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after acquiring an additional 23,849 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ASND shares. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. Cantor Fitzgerald raised their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target on the stock. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, Royal Bank of Canada started coverage on shares of Ascendis Pharma A/S in a research note on Wednesday. They issued an "outperform" rating and a $205.00 target price for the company. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $204.67.

Ascendis Pharma A/S Trading Up 3.3 %

Shares of NASDAQ ASND traded up $5.14 during mid-day trading on Thursday, hitting $163.29. The company had a trading volume of 219,554 shares, compared to its average volume of 477,876. The firm has a 50-day simple moving average of $150.17 and a two-hundred day simple moving average of $137.96. The company has a market capitalization of $9.96 billion, a PE ratio of -23.04 and a beta of 0.54. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.